News of Note—Themis’ Chikungunya vaccine, Gardasil protests and more

non
(Pixabay)

Here is some other vaccine news of note for the week.

> The European Medicines Agency has granted Themis’ phase 2 chikungunya vaccine candidate Priority Medicines (PRIME) designation, which is designed to provide enhanced regulatory support. Release

> A group of women protested at Merck’s office in Hong Kong to express their unhappiness over a shortage of Gardasil 9 in the area and to urge the firm to increase the supply. South China Morning Post article

> Healthcare mogul Patrick Soon-Shiong plans to take public a cancer vaccine biotech later this year to finance the development of six candidates currently in clinical trials against nine tumor types. FierceBiotech article

> The FDA granted a priority review for Merck's Gardasil 9 in women and men ages 27 to 45 with a PDUFA date of Oct. 6, 2018. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.